BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9426718)

  • 1. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group.
    Ellis WJ; Blumenstein BA; Ishak LM; Enfield DL
    Urology; 1997 Dec; 50(6):882-7. PubMed ID: 9426718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer.
    Leyh H; Mazeman E
    Eur Urol; 1997; 32(4):425-8. PubMed ID: 9412800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Bard Trak test with voided urine cytology in the diagnosis and follow-up of bladder tumors.
    Chautard D; Daver A; Bocquillon V; Verriele V; Colls P; Bertrand G; Soret JY
    Eur Urol; 2000 Dec; 38(6):686-90. PubMed ID: 11111185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BTA test is superior to voided urine cytology in detecting malignant bladder tumours.
    Heino A; Aaltomaa S; Ala-Opas M
    Ann Chir Gynaecol; 1999; 88(4):304-7. PubMed ID: 10661829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer.
    Leyh H; Marberger M; Conort P; Sternberg C; Pansadoro V; Pagano F; Bassi P; Boccon-Gibod L; Ravery V; Treiber U; Ishak L
    Eur Urol; 1999 Jan; 35(1):52-6. PubMed ID: 9933795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer.
    Thomas L; Leyh H; Marberger M; Bombardieri E; Bassi P; Pagano F; Pansadoro V; Sternberg CN; Boccon-Gibod L; Ravery V; Le Guludec D; Meulemans A; Conort P; Ishak L
    Clin Chem; 1999 Apr; 45(4):472-7. PubMed ID: 10102906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors.
    Giannopoulos A; Manousakas T; Mitropoulos D; Botsoli-Stergiou E; Constantinides C; Giannopoulou M; Choremi-Papadopoulou H
    Urology; 2000 Jun; 55(6):871-5. PubMed ID: 10840098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bladder tumor antigen assay as compared to voided urine cytology in the diagnosis of bladder cancer.
    Priolo G; Gontero P; Martinasso G; Mengozzi G; Formiconi A; Pelucelli G; Zitella A; Casetta G; Viberti L; Aimo G; Tizzani A
    Clin Chim Acta; 2001 Mar; 305(1-2):47-53. PubMed ID: 11249922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer?
    Mahnert B; Tauber S; Kriegmair M; Nagel D; Holdenrieder S; Hofmann K; Reiter W; Schmeller N; Stieber P
    Clin Chem Lab Med; 2003 Jan; 41(1):104-10. PubMed ID: 12636058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Bard BTA test: its mode of action, sensitivity and specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer.
    Schamhart DH; de Reijke TM; van der Poel HG; Witjes JA; de Boer EC; Kurth K; Schalken JA
    Eur Urol; 1998 Aug; 34(2):99-106. PubMed ID: 9693243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder.
    Leyh H; Hall R; Mazeman E; Blumenstein BA
    Urology; 1997 Jul; 50(1):49-53. PubMed ID: 9218018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of the BTA test in bladder cancer: a multicenter trial. BTA Study Group Japan.
    Miyanaga N; Akaza H; Kameyama S; Hachiya T; Ozono S; Kuroda M; Koga H; Koiso K
    Int J Urol; 1997 Nov; 4(6):557-60. PubMed ID: 9477183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparisons of voided urine cytology, nuclear matrix protein-22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan, China.
    Tsui KH; Chen SM; Wang TM; Juang HH; Chen CL; Sun GH; Chang PL
    Asian J Androl; 2007 Sep; 9(5):711-5. PubMed ID: 17712491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved detection of recurrent bladder cancer using the Bard BTA stat Test.
    Sarosdy MF; Hudson MA; Ellis WJ; Soloway MS; deVere White R; Sheinfeld J; Jarowenko MV; Schellhammer PF; Schervish EW; Patel JV; Chodak GW; Lamm DL; Johnson RD; Henderson M; Adams G; Blumenstein BA; Thoelke KR; Pfalzgraf RD; Murchison HA; Brunelle SL
    Urology; 1997 Sep; 50(3):349-53. PubMed ID: 9301696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BTA stat and BTA TRAK: A comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder.
    Irani J; Desgrandchamps F; Millet C; Toubert ME; Bon D; Aubert J; Le Duc A
    Eur Urol; 1999 Feb; 35(2):89-92. PubMed ID: 9933800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human complement factor H related protein test for monitoring bladder cancer.
    Raitanen MP; Marttila T; Nurmi M; Ala-Opas M; Nieminen P; Aine R; Tammela TL;
    J Urol; 2001 Feb; 165(2):374-7. PubMed ID: 11176376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A
    Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Quantification of bladder tumor antigen (BTA trak) and its correlation with bladder cancer grade and stage].
    Rodríguez Martínez JJ; Escaf Barmadah S; Allende MT; Raigoso P; Martín Benito JL; Pérez García FJ; Fernández Gómez JM
    Arch Esp Urol; 2000; 53(1):1-6. PubMed ID: 10730418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BTA TRAK urine test increases the efficacy of cytology in the diagnosis of low-grade transitional cell carcinoma of the bladder.
    Gibanel R; Ribal MJ; Filella X; Ballesta AM; Molina R; Alcaraz A; Alcover JB
    Anticancer Res; 2002; 22(2B):1157-60. PubMed ID: 12168917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.